229 related articles for article (PubMed ID: 24764569)
1. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study.
Faillie JL; Azoulay L; Patenaude V; Hillaire-Buys D; Suissa S
BMJ; 2014 Apr; 348():g2780. PubMed ID: 24764569
[TBL] [Abstract][Full Text] [Related]
2. Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.
Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Hu N; Juurlink DN; Paterson JM; Targownik LE; Turin TC; Ernst P; ; Suissa S; Dormuth CR; Hemmelgarn BR; Teare GF; Caetano P; Chateau D; Henry DA; Paterson JM; LeLorier J; Levy AR; Ernst P; Platt RW; Sketris IS
JAMA Intern Med; 2016 Oct; 176(10):1464-1473. PubMed ID: 27479930
[TBL] [Abstract][Full Text] [Related]
3. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.
Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Juurlink DN; Targownik LE; Turin TC; Paterson JM; Ernst P;
BMJ; 2016 Feb; 352():i581. PubMed ID: 26888382
[TBL] [Abstract][Full Text] [Related]
4. Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study.
Thomsen RW; Pedersen L; Møller N; Kahlert J; Beck-Nielsen H; Sørensen HT
Diabetes Care; 2015 Jun; 38(6):1089-98. PubMed ID: 25633664
[TBL] [Abstract][Full Text] [Related]
5. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.
Abrahami D; Douros A; Yin H; Yu OH; Faillie JL; Montastruc F; Platt RW; Bouganim N; Azoulay L
BMJ; 2018 Dec; 363():k4880. PubMed ID: 30518618
[TBL] [Abstract][Full Text] [Related]
6. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
Olansky L
Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512
[No Abstract] [Full Text] [Related]
7. Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.
Knapen LM; de Jong RG; Driessen JH; Keulemans YC; van Erp NP; De Bruin ML; Leufkens HG; Croes S; de Vries F
Diabetes Obes Metab; 2017 Mar; 19(3):401-411. PubMed ID: 27883260
[TBL] [Abstract][Full Text] [Related]
8. The safety of incretin based drugs.
Montori VM
BMJ; 2014 Apr; 348():g2779. PubMed ID: 24764568
[No Abstract] [Full Text] [Related]
9. Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan.
Chang HY; Hsieh CF; Singh S; Tang W; Chiang YT; Huang WF
Pharmacoepidemiol Drug Saf; 2015 Jun; 24(6):567-75. PubMed ID: 25851403
[TBL] [Abstract][Full Text] [Related]
10. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.
Tseng CM; Liao WC; Chang CY; Lee CT; Tseng CH; Hsu YC; Lin JT
Pancreatology; 2017; 17(1):76-82. PubMed ID: 27743712
[TBL] [Abstract][Full Text] [Related]
11. ACP Journal Club. Incretin use was not associated with increased risk for acute pancreatitis.
Schectman J
Ann Intern Med; 2015 Jun; 162(12):JC12. PubMed ID: 26075777
[No Abstract] [Full Text] [Related]
12. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
Li L; Shen J; Bala MM; Busse JW; Ebrahim S; Vandvik PO; Rios LP; Malaga G; Wong E; Sohani Z; Guyatt GH; Sun X
BMJ; 2014 Apr; 348():g2366. PubMed ID: 24736555
[TBL] [Abstract][Full Text] [Related]
13. Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.
Smits MM; Muskiet MH; Tonneijck L; van Raalte DH
Diabetes Care; 2015 Jul; 38(7):e106-7. PubMed ID: 26106231
[No Abstract] [Full Text] [Related]
14. Response to Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.
Thomsen RW; Pedersen L; Møller N; Kahlert J; Beck-Nielsen H; Sørensen HT
Diabetes Care; 2015 Jul; 38(7):e108-9. PubMed ID: 26106232
[No Abstract] [Full Text] [Related]
15. Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes.
Abrahami D; Yin H; Yu OHY; Pollak MN; Azoulay L
Epidemiology; 2018 Mar; 29(2):246-253. PubMed ID: 29283894
[TBL] [Abstract][Full Text] [Related]
16. Does the use of incretin-based medications increase the risk of cancer in patients with type-2 diabetes mellitus?
Karp I; Sivaswamy A; Booth C
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):489-499. PubMed ID: 30779266
[TBL] [Abstract][Full Text] [Related]
17. Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies.
Wang T; Wang F; Gou Z; Tang H; Li C; Shi L; Zhai S
Diabetes Obes Metab; 2015 Jan; 17(1):32-41. PubMed ID: 25200423
[TBL] [Abstract][Full Text] [Related]
18. Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes.
Gamble JM; Donnan JR; Chibrikov E; Twells LK; Midodzi WK; Majumdar SR
Sci Rep; 2018 Oct; 8(1):15142. PubMed ID: 30310100
[TBL] [Abstract][Full Text] [Related]
19. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study.
Knapen LM; van Dalem J; Keulemans YC; van Erp NP; Bazelier MT; De Bruin ML; Leufkens HG; Croes S; Neef C; de Vries F; Driessen JH
Diabetes Obes Metab; 2016 Mar; 18(3):258-65. PubMed ID: 26537555
[TBL] [Abstract][Full Text] [Related]
20. Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials.
Roshanov PS; Dennis BB
Diabetes Res Clin Pract; 2015 Dec; 110(3):e13-7. PubMed ID: 26643128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
